AZD-3965

N/A

Report date: 2025/11/17 20:01:59
NME

Base Information

Drug NameAZD-3965
Drug Alias NameAZD-3965
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMonocarboxylate transporter 1 inhibitorsMonocarboxylate transporter 2 inhibitors
TargetsMonocarboxylate transporter 2Monocarboxylate transporter 1
Therapy Area/IndicationsSolid tumoursLymphoma, Large B-Cell, DiffuseBurkitt Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma, Large B-Cell, DiffuseBurkitt Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A